One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
Hong Kong stock "the first stock of innovative drugs for kidney disease" LifeBond Medicine (09637) has introduced 11 top cornerstone investors, creating the strongest lineup in the Hong Kong stock 18A market in recent years.
Hong Kong stock "the first stock of innovative drugs for kidney disease" LIBANG Medicine (09637) was listed from June 18 to June 24, 2026, and is expected to officially start trading on the Hong Kong Stock Exchange at 9 am on June 29. This innovative drug company specializing in kidney disease not only has a complete pipeline matrix of "1 commercial product + 7 clinical stage candidate drugs", but also has gathered 11 cornerstone investors including global sovereign funds, century-old asset management, professional life science funds, and industrial capital under the overall low performance of the Hong Kong stock biopharmaceutical sector, setting a ceiling for the cornerstone lineup in the 18A market in recent years.
Related Articles
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
New stock preview | How deep is the barrier of Guirewat's radical transformation into the "champion of household energy storage"?
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.
Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.
New stock preview | How deep is the barrier of Guirewat's radical transformation into the "champion of household energy storage"?
RECOMMEND
